Stock A086460 CURABLE. INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Curable. Inc.

Equities

A086460

KR7086460003

End-of-day quote Korea S.E.
Other stock markets
 18:00:00 2024-05-30 EDT 		5-day change 1st Jan Change
2,610 KRW -14.98% Intraday chart for Curable. Inc. -45.45% -60.27%
2023 Curable. Inc. agreed to acquire 8.5% stake in Pharma Biotech Korea Co., Ltd from Pharma Biotech Korea for KRW 8.5 billion. CI
2023 Curable. Inc. announced that it has received KRW 5.0009986 billion in funding from GW Vitek CO.,LTD. CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Curable. Inc. agreed to acquire 8.5% stake in Pharma Biotech Korea Co., Ltd from Pharma Biotech Korea for KRW 8.5 billion.
CI
Curable. Inc. announced that it has received KRW 5.0009986 billion in funding from GW Vitek CO.,LTD.
CI
SNP Genetics Inc. announced that it has received KRW 10 billion in funding from Kalis BNT Co., Ltd.
CI
Curable. Inc. announced that it expects to receive KRW 9.999995 billion in funding from GW Vitek CO.,LTD.
CI
SNP Genetics Inc. announced that it expects to receive KRW 10 billion in funding from Kalis BNT Co., Ltd.
CI
An unknown buyer agreed to acquire 16.82% of stake in SNP Genetics Inc. from Jo, Jin-hwan and others for KRW 3.7 billion.
CI
SNP Genetics Inc. announced that it has received KRW 2.49999872 billion in funding
CI
SNP Genetics Inc. announced that it expects to receive KRW 2 billion in funding
CI
SNP Genetics Inc. announced that it expects to receive KRW 2.49999872 billion in funding
CI
GW Vitek CO.,LTD. agreed to acquire a 40.7% stake in SNP Genetics Inc. from Hyoung-doo Shin and Myung-cheol Kim for KRW 9.4 billion.
CI
Tranche Update on SNP Genetics Inc.'s Equity Buyback Plan announced on November 2, 2020.
CI
SNP Genetics Inc.'s Equity Buyback announced on November 2, 2020, has expired with 110,000 shares, for KRW 104.72 million.
CI
SNP Genetics Inc. announces an Equity Buyback for 277,777 shares, for KRW 1,000 million.
CI
SNP Genetics Inc. authorizes a Buyback Plan.
CI
SNP Genetics Inc. cancelled the acquisition of an additional 0.99% stake in Enzychem Lifesciences Corporation from Capitalworks Investment Co.,Ltd.
CI
SNP Genetics Inc. acquired an additional 0.82% stake in Enzychem Lifesciences Corporation.
CI
SNP Genetics Inc. acquired an additional 0.02% stake in Enzychem Lifesciences Corporation.
CI
SNP Genetics Inc. agreed to acquire an additional 0.99% stake in Enzychem Lifesciences Corporation from Capitalworks Investment Co.,Ltd. for KRW 780 million.
CI
SNP Genetics Inc. acquired an additional 0.05% stake in Enzychem Lifesciences Corporation.
CI
SNP Genetics Inc. acquired an additional 0.025% stake in Enzychem Lifesciences Corporation.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A086460 Stock
  4. News Curable. Inc.